• Fus3-MAPK/RNS1 Cascade Regulates Fungal Entomopathogenicity

  2026-08-03

  Meng et al. reveal a previously uncharacterized regulatory cascade in Metarhizium robertsii, where Fus3-MAPK directly phosphorylates RNS1, enabling adaptive utilization of diverse nitrogen and carbon sources and enhancing entomopathogenicity. This mechanistic insight advances fungal pathogenesis research and supports new approaches for phosphorylation-dependent signaling analysis.

• PAD4-IN-2 TFA: Targeted NET Inhibition for Tumor Microenviro

  2026-08-02

  This thought-leadership article explores the mechanistic basis and translational potential of PAD4-IN-2 TFA (Compound 5i TFA), a meta-phenylboronic acid-modified PAD4 inhibitor designed for tumor-selective inhibition of histone H3 citrullination and neutrophil extracellular trap (NET) formation. Drawing on recent mechanistic evidence, the article outlines strategic guidance for translational researchers, discusses PAD4-IN-2 TFA’s differentiation from earlier PAD4 inhibitors, and delineates experimental protocols and future outlooks for leveraging this compound in cancer research.

• DAPT (GSI-IX): Strategic Inhibition of Notch in Translationa

  2026-08-01

  This thought-leadership article bridges mechanistic insight and translational strategy for researchers leveraging DAPT (GSI-IX) as a precise γ-secretase inhibitor. By dissecting recent mechanistic studies—including Thymosin-β 4’s regulation of angiogenesis via Notch/NF-κB—and contextualizing DAPT’s validated impact across Alzheimer’s, cancer, and vascular models, this piece delivers actionable guidance on experimental design, protocol optimization, and the translational promise of Notch pathway modulation. APExBIO’s DAPT is highlighted as a proven tool, with competitive and future-oriented perspectives.

• Novel FLCN Mutations and mRNA Rescue in Birt-Hogg-Dubé Syndr

  2026-07-31

  This study identifies a previously unreported pathogenic FLCN nonsense mutation and reclassifies a missense variant as pathogenic in Birt-Hogg-Dubé syndrome (BHD) families. Critically, the authors demonstrate that exogenous FLCN mRNA delivery can restore protein expression and normalize mTORC1 signaling in vitro, providing foundational evidence for mRNA-based therapeutic strategies in rare genetic disorders.

• Strategic Protease Inhibition for Reproducible Translational

  2026-07-31

  Explore how mechanistic insights and strategic use of EDTA-free protease inhibitor cocktails—anchored by APExBIO’s validated formulation—empower translational researchers to preserve protein integrity for high-stakes assays, drive reproducibility, and bridge the gap between advanced immunology and robust protein workflows.

• PR-619: Broad-Spectrum Deubiquitylating Enzymes Inhibitor in

  2026-07-30

  PR-619 empowers researchers to dissect the ubiquitination pathway with precision, uniquely accumulating ubiquitinated proteins without impeding proteasomal activity. Its versatility spans cancer biology, neurodegeneration, and autophagy research, making it an indispensable tool for advanced cell-based assays.

• Cy5 amine (non-sulfonated): Technical Guidance for Labeling

  2026-07-30

  Cy5 amine (non-sulfonated) provides a bright, photostable fluorophore for covalent labeling of proteins, peptides, and polymers in workflows that require water-insoluble dyes. It is not suitable for direct aqueous-phase labeling or for use in diagnostic or medical applications. Proper solvent handling and protocol setup are essential for reliable conjugation and fluorescence detection.

• Live-Dead Bacterial Staining Kit: Precision Viability in Nan

  2026-07-29

  Unlock reproducible, high-resolution bacterial viability assessment in advanced infection and nanomaterial workflows with the Live-Dead Bacterial Staining Kit. This guide bridges innovative jaw osteomyelitis models with robust, dual-fluorescent staining protocols—empowering microbiology and translational research teams to troubleshoot, optimize, and interpret viability results with confidence.

• Tetrahydromagnolol: Applied Workflows for Peripheral CB2 Res

  2026-07-29

  Tetrahydromagnolol, a highly selective peripheral CB2 receptor agonist, enables precise dissection of cannabinoid signaling in advanced analgesic, anti-inflammatory, and metastatic models. Its dual CB2 agonism and GPR55 antagonism empower researchers to map GPCR-driven pathways with superior selectivity, facilitating breakthrough insights into metastasis and inflammation.

• 25-Hydroxycholesterol–Lysosomal AMPK Axis Reprograms Tumor M

  2026-07-28

  Xiao et al. (2024) reveal how lysosomal 25-hydroxycholesterol activates AMPKα, leading to STAT6-dependent immunosuppressive programming in tumor-associated macrophages. These findings highlight CH25H as a crucial immunometabolic checkpoint, suggesting new strategies to remodel the tumor microenvironment and improve immunotherapy efficacy.

• IWP-L6: Precision Porcupine Inhibitor for Wnt Pathway Assays

  2026-07-28

  IWP-L6 empowers researchers to dissect and modulate Wnt signaling with unmatched precision, enabling breakthroughs in developmental biology and metabolic research. Its sub-nanomolar Porcupine inhibition redefines workflow reproducibility, particularly in branching morphogenesis and zebrafish regeneration assays.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Research

  2026-07-27

  Masitinib (AB1010) is a selective tyrosine kinase inhibitor for research applications where precise inhibition of KIT, PDGFRα, and PDGFRβ is required, such as in cancer biology, mastocytosis, and inflammation studies. It is not suitable for protocols demanding broad-spectrum kinase inhibition or compatibility with aqueous or ethanol-based solvents.

• VX-702: Selective p38α MAPK Inhibition and Phosphatase Targe

  2026-07-27

  Explore how VX-702, a potent p38α MAPK inhibitor, uniquely exploits kinase conformation to enhance research on cytokine regulation and inflammation. This article uncovers new mechanistic insights with practical guidance distinct from standard approaches.

• Dissecting Drug Response Metrics: New In Vitro Cancer Models

  2026-07-26

  Schwartz's dissertation rigorously distinguishes between relative and fractional viability as in vitro drug response metrics, revealing their distinct roles in assessing proliferation arrest versus cell death. These findings inform more nuanced experimental design and data interpretation in cancer pharmacology.

• Ziprasidone HCl: Translational Workflows from Bench to Oncol

  2026-07-25

  Ziprasidone Hydrochloride is redefining translational research through its dual-action as a serotonin-dopamine receptor antagonist and GOT1 inhibitor, supporting both neuroscience and cancer metabolism studies. This article delivers actionable protocols, troubleshooting guidance, and a critical synthesis of recent clinical and preclinical findings to help researchers maximize the utility of Ziprasidone HCl from APExBIO.

14582 records 2/973 page Previous Next 12345 下5页 Last page